Lumera Labs

Tirzepatide Injection Pen — Patient Instructions (24U example)

Authoritative, patient-friendly instructions for using a dial-based pen. This page is educational and does not replace your device Instructions for Use or your prescriber’s advice.

Last reviewed: 2025‑09‑04

Overview

Tirzepatide is usually injected once weekly under the skin (subcutaneous). Some pens allow setting the dose by units. The example below uses 24U. Your actual dose and schedule may differ—follow your prescriber.

  • Common injection sites: abdomen, thigh, upper arm. Rotate the site with each injection.
  • Use a new sterile needle for every injection. Do not share needles or pens.

Back to top

Before You Use

  • Wash hands and prepare a clean surface.
  • Check the label and expiry; solution should be clear and particle‑free.
  • Allow the pen to reach room temperature (about 10–15 minutes) if taken from the refrigerator.
  • Gather supplies: new sterile needle, alcohol swab, cotton/gauze, sharps container.

Back to top

Dosage & Administration (24U example)

  1. Attach a new needle. Remove both inner and outer caps after attaching.
  2. Prime the pen. Turn to 2U and press with the needle pointing up until a drop is seen. Repeat if needed to remove air bubbles.
  3. Set the dose to 24U. Rotate the dial until the window shows 24 units.
  4. Prepare the injection site. Clean with an alcohol swab and allow to dry.
  5. Inject subcutaneously. Insert at 90° (45° if very slim). Press and hold until the dial returns to 0, then continue holding for 10 seconds before withdrawing.
  6. Apply gentle pressure. Use cotton/gauze if needed; do not rub.
  7. Remove the needle and dispose safely. Place used needles in a sharps container.
Frequency: Inject once weekly, on the same day if possible. If your prescriber adjusts your dose, follow their schedule.

Back to top

Dosage

The recommended starting dosage of Tirzepatide is 2.5 mg (25U) injected subcutaneously once weekly. Follow the dosage escalation below to reduce the risk of gastrointestinal adverse reactions. The 2.5 mg (25U) dosage is for treatment initiation and is not intended for glycemic control.

After 4 weeks, increase the dosage to 5 mg (50U) injected subcutaneously once weekly.

If additional glycemic control is needed, increase the dosage in 2.5 mg (25U) increments after at least 4 weeks on the current dose.

The maximum dosage of Tirzepatide is 15 mg injected subcutaneously once weekly.

If a dose is missed, instruct patients to administer Tirzepatide as soon as possible within 4 days (96 hours) after the missed dose. If more than 4 days have passed, skip the missed dose and administer the next dose on the regularly scheduled day. In each case, patients can then resume their regular once weekly dosing schedule.

The day of weekly administration can be changed, if necessary, as long as the time between the two doses is at least 3 days (72 hours).

Back to top

Missed Dose

If you remember within 4 days, inject as soon as possible and resume weekly from that day. If more than 4 days have passed, skip the missed dose and take the next dose on your regular day. Do not double the dose.

Back to top

Storage & Handling

  • Refrigerate at 2–8°C. Do not freeze. Protect from heat and direct light.
  • Follow the device label for in‑use storage time after first use.
  • Keep out of reach of children and pets.

Back to top

Disposal

Place used needles and sharps in a puncture‑resistant sharps container. Follow local regulations or clinic guidance for disposal.

Back to top

Warnings & When to Seek Care

  • Stop and seek medical help for severe, persistent abdominal pain; signs of allergic reaction (rash, swelling, difficulty breathing); or symptoms of very low blood sugar (dizziness, shaking, sweating).
  • Do not use if the solution appears cloudy, discolored, or contains particles.
  • Use only the dose directed by your prescriber. Device models differ; follow your specific Instructions for Use.

Back to top

References

  • Instructions for Use and Prescribing Information for your specific pen model.
  • Guidance from your healthcare professional or clinic.

Back to top